Edrophrium drug

Reading File

Finding Sources

Searching the Web

edrophonium drug mechanism uses myasthenia gravis Tensilon test pharmacology

Reading File

Finding Sources

Reading File

Loading Image

Searching Images

edrophonium Tensilon test myasthenia gravis neuromuscular junction acetylcholinesterase

This clinical photograph is a side-by-side comparison illustrating a positive Tensilon (edrophonium) test in a patient with Myasthenia Gravis (MG). Panel A shows the patient's orbital region at baseline, demonstrating significant bilateral asymmetrical ptosis (drooping of the upper eyelids). The left eyelid is more severely affected, covering a substantial portion of the visual axis. Panel B shows the same patient after the administration of edrophonium, an acetylcholinesterase inhibitor. There is a marked improvement in the bilateral ptosis, characterized by an increased palpebral fissure width and elevation of the upper lid margins, exposing more of the iris and pupil. This visual change is a classic diagnostic indicator for disorders of the neuromuscular junction, specifically MG associated with anti-acetylcholine receptor (AchR) antibodies. The image serves as a clinical teaching tool for neurology and ophthalmology to demonstrate the transient reversal of fatiguable muscle weakness through pharmacological intervention.

Two side-by-side clinical photographs labeled A and B demonstrate a bedside ice pack test in a patient with suspected myasthenia gravis. Image A (Before Ice Pack Test) shows significant left-sided blepharoptosis, with the upper eyelid drooping to partially cover the pupil (indicated by a black arrow). Image B (After Ice Pack Test) demonstrates a positive result, where the left eyelid shows temporary elevation and resolution of ptosis (indicated by a blue arrow) following local cooling. The patient is shown in a clinical setting wearing a blue surgical cap, a nasal cannula for oxygen delivery, and an adhesive nasal strip for stabilization. This comparative series illustrates the clinical utility of the ice pack test, which inhibits acetylcholinesterase activity at the neuromuscular junction to temporarily improve muscle strength in myasthenic patients. The images highlight key diagnostic physical exam findings in neuro-ophthalmology and neuromuscular medicine.

This set of six clinical photographs (A-F) illustrates the variability of the ice test in a patient with myasthenia gravis presenting with bilateral asymmetric ptosis. The images are arranged in pairs representing three different days, showing the patient's eyes before and after a 2-minute ice application. Frames A, C, and E show baseline bilateral blepharoptosis with varying degrees of upper eyelid drooping obscuring the pupil and iris. Frames B, D, and F show the post-intervention state. The series demonstrates three distinct clinical responses in the right eye: (B) a negative result with no significant change, (D) an equivocal result showing subtle 1.0 mm elevation, and (F) a positive result with a marked 2.0 mm increase in the palpebral fissure. This comparison serves as an educational tool for neurology and ophthalmology students to understand the fluctuating nature of neuromuscular junction disorders and the diagnostic utility (and inconsistency) of the ice pack test, which temporarily improves ptosis by inhibiting acetylcholinesterase at the motor endplate.

Here is a complete pharmacology overview of Edrophonium based on authoritative medical textbooks:

Edrophonium (Tensilon)

Drug Class & Mechanism of Action

Edrophonium is the prototype short-acting, reversible acetylcholinesterase (AChE) inhibitor. It binds reversibly to the active center of AChE, preventing hydrolysis of acetylcholine (ACh). This leads to ACh accumulation in the synaptic cleft, prolonging and intensifying its interaction with both muscarinic and nicotinic receptors.

Mechanism of indirect cholinergic agonists - Edrophonium inhibits AChE, preventing ACh breakdown and increasing intracellular response

Edrophonium (along with echothiophate, neostigmine, and physostigmine) blocks AChE, preventing ACh degradation and amplifying cholinergic signaling at the neuromuscular junction.

Chemical structure: Quaternary amine - charged and polar, so it cannot cross the blood-brain barrier. Its actions are therefore limited to the periphery with no CNS effects.
Elimination: Rapid renal elimination accounts for its very short duration of action.

(Lippincott Illustrated Reviews Pharmacology)

Pharmacokinetics

Parameter	Value
Onset	30-60 seconds (IV)
Peak effect	< 2 minutes
Duration	5-20 minutes
Route	Intravenous (IV)
Elimination	Renal

(Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e; Tintinalli's Emergency Medicine)

Clinical Uses

1. Diagnosis of Myasthenia Gravis (MG) - "Tensilon Test"

Myasthenia gravis is an autoimmune disease where antibodies against nicotinic ACh receptors at the NMJ reduce available receptors, causing muscle weakness. When edrophonium is given IV, the resulting increase in available ACh improves muscle strength transiently in MG patients.

Test Protocol:

Give 2 mg IV as a test dose; wait 45 seconds
If no response, give an additional 8 mg IV
Positive result: Visible improvement in muscle strength (e.g., resolution of ptosis, fusion of diplopia) lasting ~5 minutes = confirms MG

(Katzung's Basic and Clinical Pharmacology, 16th Ed.)

Diagnostic accuracy: Reported positive in 60-95% of patients with ocular MG and 72-95% with generalized MG. (Bradley and Daroff's Neurology in Clinical Practice)

Clinical photo - Positive Tensilon Test:

Positive Tensilon (edrophonium) test showing dramatic resolution of bilateral ptosis in a myasthenia gravis patient before and after edrophonium administration

Before (A) and after (B) edrophonium: marked improvement in bilateral ptosis is the classic positive response.

Important note: The edrophonium test has lost favor as a primary diagnostic tool due to the widespread availability of autoantibody testing (anti-AChR, anti-MuSK antibodies). Edrophonium is also increasingly difficult to obtain globally and has not been available in the United States since 2018. (Barash's Clinical Anesthesia, 9e; Bradley & Daroff's Neurology)

2. Differentiating Myasthenic Crisis vs. Cholinergic Crisis

This is one of the most important clinical uses. Patients on chronic anticholinesterase therapy may deteriorate - and it can be hard to tell if they are under-treated (myasthenic crisis) or over-treated (cholinergic crisis).

Feature	Myasthenic Crisis	Cholinergic Crisis
Cause	Undermedication / disease exacerbation	Overmedication (excess ACh)
After edrophonium	Muscle strength improves	Weakness worsens; fasciculations, respiratory depression
Treatment	Increase anticholinesterases (pyridostigmine)	Atropine; ventilatory support

Dose used: 1-2 mg IV (small doses are used for this differentiation to avoid precipitating worsening in cholinergic crisis)
Caution: Equipment for ventilatory support must be available due to the risk of respiratory arrest

(Tintinalli's Emergency Medicine; Katzung's Pharmacology)

3. Reversal of Neuromuscular Blockade (Anesthesia)

Edrophonium is used to reverse non-depolarizing neuromuscular blocking agents. It has a significantly faster onset than neostigmine (peak antagonism in < 2 minutes).

Dose: 0.5-1.0 mg/kg IV
Co-administer with atropine (not glycopyrrolate) because atropine's fast onset matches that of edrophonium - 0.014 mg atropine per 1 mg edrophonium
Preferred for mivacurium reversal: Unlike neostigmine, edrophonium does not inhibit plasma cholinesterase (which is required to metabolize mivacurium), making it uniquely useful here

(Barash's Clinical Anesthesia 9e; Morgan & Mikhail's Clinical Anesthesiology 7e)

4. Pediatric Dosing (Myasthenia Diagnosis)

Total edrophonium IV dose in children: 0.15 mg/kg, not to exceed 10 mg
Give 1/10th of the total dose as a test dose first to assess for adverse cholinergic effects

(Tintinalli's Emergency Medicine)

Adverse Effects / Cholinergic Toxicity

Because edrophonium enhances ACh at all cholinergic sites, it can produce muscarinic and nicotinic side effects:

Muscarinic (SLUD):

Salivation, lacrimation, urination, defecation
Bradycardia, hypotension
Increased bronchial secretions, bronchospasm
Miosis, abdominal cramps, nausea, vomiting

Nicotinic:

Muscle fasciculations
Skeletal muscle weakness/paralysis (at high doses - depolarizing blockade)
Respiratory paralysis (most dangerous)

Rare but serious: Bradycardia, syncope, respiratory arrest (especially in ocular testing if cardiac monitoring is not present)

(Wills Eye Manual; Lippincott Pharmacology)

Comparison with Other Anticholinesterases

Drug	Duration	CNS Entry	Key Use
Edrophonium	5-20 min (short)	No (quaternary)	Diagnosis of MG, crisis differentiation, reversal
Neostigmine	30 min - 2 hr	No (quaternary)	Reversal of NMB, MG management
Pyridostigmine	3-6 hr	No (quaternary)	Long-term MG management
Physostigmine	30 min - 2 hr	Yes (tertiary)	Anticholinergic toxidrome reversal

Key Points Summary

Prototype short-acting AChE inhibitor - reversible, quaternary amine
Onset 30-60 sec, duration 5-20 min - fastest onset of all anticholinesterases
Primary use: Tensilon test for MG diagnosis and crisis differentiation
Anesthesia: Reversal of non-depolarizing blockade; preferred for mivacurium reversal (does not inhibit plasma cholinesterase)
Antidote for cholinergic crisis: Atropine (muscarinic blocker)
No CNS effects due to quaternary structure
Availability: Withdrawn from the US market in 2018; increasingly unavailable worldwide

Curb

Asking for Preferences

Reading File

Finding Sources

Searching the Web

CURB-65 score pneumonia criteria management 2024 guidelines

Reading File

Here is a complete breakdown of the CURB-65 Score:

CURB-65 Score - Community-Acquired Pneumonia (CAP) Severity

What is CURB-65?

CURB-65 is a validated clinical severity scoring tool for community-acquired pneumonia (CAP). It is used to estimate 30-day mortality and guide the decision of outpatient vs. inpatient vs. ICU-level management. It was developed by the British Thoracic Society (BTS) as a simpler alternative to the Pneumonia Severity Index (PSI).

The 5 Criteria (1 point each)

Letter	Parameter	Threshold
C	Confusion	New confusion (abbreviated Mental Test score ≤8, or disorientation to person, place, or time)
U	Blood Urea nitrogen	BUN >7 mmol/L (>19 mg/dL)
R	Respiratory rate	≥ 30 breaths/min
B	Blood pressure	Systolic < 90 mmHg OR diastolic ≤ 60 mmHg
65	Age	≥ 65 years

Maximum score = 5

Score Interpretation & Management

Score	Mortality Risk	Management
0	~1.5% (30-day)	Outpatient treatment
1	Low risk	Outpatient (consider admission if age ≥65 is the only point)
2	Intermediate (3-15%)	Hospital admission OR virtual ward/same-day emergency care
3-5	High (>15-22%)	Inpatient ± ICU consideration

Key note: Scores of ≥3 carry a 22% overall 30-day mortality and may require ICU-level admission.

(Harrison's Principles of Internal Medicine 22E, 2025; Fishman's Pulmonary Diseases)

CRB-65 (Simplified Version - No Labs Needed)

When lab testing is not immediately available (e.g., community/primary care settings), CRB-65 drops the BUN criterion:

CRB-65 Score	Action
0	Manage in primary care (low risk)
1	Consider referral to hospital or virtual ward
≥2	Refer to hospital

(NICE Pneumonia Guidelines, 2025)

CURB-65 vs. PSI - Quick Comparison

Feature	CURB-65	PSI
Variables	5	20
Complexity	Simple, bedside	Complex, calculator needed
Best for	Identifying high-risk patients	Identifying low-risk patients
Preferred by	British Thoracic Society, NICE	IDSA-ATS guidelines
Validation	Good	More robust

PSI has superior test characteristics and greater validation, but CURB-65 is preferred in practice for its simplicity and integration into electronic decision-support tools. (Fishman's Pulmonary Diseases; Harrison's 22E)

IDSA/ATS Criteria for ICU Admission (Separate from CURB-65)

CURB-65 is not accurate for determining ICU need. The following criteria override CURB-65:

Major criteria (either one = direct ICU admission):

Septic shock requiring vasopressors
Acute respiratory failure requiring mechanical ventilation

Minor criteria (≥3 of 9 = ICU or high-monitoring unit):

Respiratory rate ≥30 breaths/min
PaO2/FiO2 ratio ≤250
Multilobar infiltrates
Confusion/disorientation
Uremia (BUN ≥20 mg/dL)
Leukopenia (WBC <4,000 cells/mm³)
Thrombocytopenia (platelets <100,000/mm³)
Hypothermia (core temp <36°C)
Hypotension requiring aggressive fluid resuscitation

(Harrison's Principles of Internal Medicine 22E)

Important Caveats

Clinical judgment always takes priority - scores support but do not replace clinical assessment
CURB-65 does not account for comorbidities, oxygenation (SpO2), ability to take oral medications, or social factors (e.g., homelessness, cognitive impairment)
If O2 saturation on room air is <92%, hospitalization is generally needed regardless of score
A low CURB-65 score does not exclude severe pneumonia, especially in patients with significant comorbidities or frailty
The score can be misleading in pregnancy

(NICE Guidelines 2025; BMJ Best Practice CAP guidelines)

This is a shared conversation. Sign in to Orris to start your own chat.